ALT

ALT EBITDA Growth

-5.22%TTM

Period ending:

ALT TTM EBITDA YoY %%
ALT TTM EBITDA YoY %208.32%-1144.79%
2007-06-302026-06-30

Source: Financial Modeling Prep (FMP). Trailing twelve months (TTM). TTM flows use four complete reported quarters. Growth compares with the corresponding period one year earlier.

ALT ebitda growth history

Year-over-year EBITDA growth rate. The available trailing twelve months (ttm) series contains 77 observations from Jun 30, 2007 to Jun 30, 2026.

Altimmune Inc EBITDA Growth — Trailing twelve months (TTM)
Period endingEBITDA Growth
-5.2235%
2.7327%
8.212%
17.4521%
11.2086%
-0.2807%
-10.0431%
-30.676%
-23.417%
-7.2522%
-0.6628%
9.5703%
16.1233%
8.7785%
-0.4058%
-6.5526%
-46.1478%
-37.8945%
-45.3322%
-77.1286%
-71.5211%
-188.5704%
-197.6762%
-5.103%
-8.2788%
45.3554%
55.9393%
-46.5414%
39.1589%
17.2623%
11.1786%
27.7177%
-308.2035%
-336.8764%
-405.3483%
-414.042%
-236.0726%
-137.4253%
-361.9671%
-83.9849%
45.7781%
15.5489%
77.3785%
61.7166%
26.0612%
47.9408%
6.472%
-61.5673%
-114.6769%
-157.3496%
-76.2576%
-23.0196%
50.2123%
62.2925%
47.9929%
54.5858%
-1.6809%
8.3651%
37.8665%
41.4931%
62.0008%
52.7261%
28.3477%
10.1209%
-28.5588%
-839.6207%
-1,013.8407%
-676.2329%
-537.5669%
74.7463%
75.6188%
12.8167%
7.3301%
-114.4074%
-278.2751%
-38.8587%
-472.1977%

Compare ebitda growth

All ALT financial metrics · ALT stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.